76 related articles for article (PubMed ID: 9225791)
1. Three-dimensional dosimetry for intralesional radionuclide therapy using mathematical modeling and multimodality imaging.
Flux GD; Webb S; Ott RJ; Chittenden SJ; Thomas R
J Nucl Med; 1997 Jul; 38(7):1059-66. PubMed ID: 9225791
[TBL] [Abstract][Full Text] [Related]
2. Implementation and evaluation of patient-specific three-dimensional internal dosimetry.
Kolbert KS; Sgouros G; Scott AM; Bronstein JE; Malane RA; Zhang J; Kalaigian H; McNamara S; Schwartz L; Larson SM
J Nucl Med; 1997 Feb; 38(2):301-8. PubMed ID: 9025759
[TBL] [Abstract][Full Text] [Related]
3. Development of a SPECT-based three-dimensional treatment planning system for radioimmunotherapy.
Giap HB; Macey DJ; Podoloff DA
J Nucl Med; 1995 Oct; 36(10):1885-94. PubMed ID: 7562060
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity of monoclonal antibody distribution and radiation dose in tumors: a modeling analysis.
Fujimori K
Hokkaido Igaku Zasshi; 1991 May; 66(3):369-84. PubMed ID: 1885162
[TBL] [Abstract][Full Text] [Related]
5. Integrated microscopic-macroscopic pharmacology of monoclonal antibody radioconjugates: the radiation dose distribution.
Fujimori K; Fisher DR; Weinstein JN
Cancer Res; 1991 Sep; 51(18):4821-7. PubMed ID: 1893374
[TBL] [Abstract][Full Text] [Related]
6. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
Wessels BW; Bolch WE; Bouchet LG; Breitz HB; Denardo GL; Meredith RF; Stabin MG; Sgouros G;
J Nucl Med; 2004 Oct; 45(10):1725-33. PubMed ID: 15471841
[TBL] [Abstract][Full Text] [Related]
8. A radionuclide therapy treatment planning and dose estimation system.
Liu A; Williams LE; Lopatin G; Yamauchi DM; Wong JY; Raubitschek AA
J Nucl Med; 1999 Jul; 40(7):1151-3. PubMed ID: 10405136
[TBL] [Abstract][Full Text] [Related]
9. A method for patient-specific absorbed dose estimation for internal beta emitters.
Williams LE; Liu A; Raubitschek AA; Wong JY
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3015s-3019s. PubMed ID: 10541337
[TBL] [Abstract][Full Text] [Related]
10. A three-dimensional transport model for determining absorbed fractions of energy for electrons within trabecular bone.
Bouchet LG; Jokisch DW; Bolch WE
J Nucl Med; 1999 Nov; 40(11):1947-66. PubMed ID: 10565793
[TBL] [Abstract][Full Text] [Related]
11. Treatment planning for internal radionuclide therapy: three-dimensional dosimetry for nonuniformly distributed radionuclides.
Sgouros G; Barest G; Thekkumthala J; Chui C; Mohan R; Bigler RE; Zanzonico PB
J Nucl Med; 1990 Nov; 31(11):1884-91. PubMed ID: 2231006
[TBL] [Abstract][Full Text] [Related]
12. Three-dimensional dosimetry for radioimmunotherapy treatment planning.
Sgouros G; Chiu S; Pentlow KS; Brewster LJ; Kalaigian H; Baldwin B; Daghighian F; Graham MC; Larson SM; Mohan R
J Nucl Med; 1993 Sep; 34(9):1595-601. PubMed ID: 8394886
[TBL] [Abstract][Full Text] [Related]
13. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
14. Monte Carlo MCNP-4B-based absorbed dose distribution estimates for patient-specific dosimetry.
Yoriyaz H; Stabin MG; dos Santos A
J Nucl Med; 2001 Apr; 42(4):662-9. PubMed ID: 11337557
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the influence of setup uncertainties on treatment planning for focal liver tumors.
Balter JM; Brock KK; Lam KL; Tatro D; Dawson LA; McShan DL; Ten Haken RK
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):610-4. PubMed ID: 16095848
[TBL] [Abstract][Full Text] [Related]
16. Single-dose versus fractionated radioimmunotherapy: model comparisons for uniform tumor dosimetry.
O'Donoghue JA; Sgouros G; Divgi CR; Humm JL
J Nucl Med; 2000 Mar; 41(3):538-47. PubMed ID: 10716330
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic modeling and absorbed dose estimation for chimeric anti-CEA antibody in humans.
Odom-Maryon TL; Williams LE; Chai A; Lopatin G; Liu A; Wong YC; Chou J; Clarke KG; Raubitschek AA
J Nucl Med; 1997 Dec; 38(12):1959-66. PubMed ID: 9430477
[TBL] [Abstract][Full Text] [Related]
18. Use of the fast Hartley transform for three-dimensional dose calculation in radionuclide therapy.
Erdi AK; Yorke ED; Loew MH; Erdi YE; Sarfaraz M; Wessels BW
Med Phys; 1998 Nov; 25(11):2226-33. PubMed ID: 9829250
[TBL] [Abstract][Full Text] [Related]
19. Validation of an analytical expression for the absorbed dose from a spherical beta source geometry and its application to micrometastatic radionuclide therapy.
Sarfaraz M; Wessels BW
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3020s-3023s. PubMed ID: 10541338
[TBL] [Abstract][Full Text] [Related]
20. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation.
Wahl RL; Kroll S; Zasadny KR
J Nucl Med; 1998 Aug; 39(8 Suppl):14S-20S. PubMed ID: 9708566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
